• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Introduction to 1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol (CAS No: 1245772-78-4)

1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol, identified by the Chemical Abstracts Service Number (CAS No) 1245772-78-4, is a significant compound in the realm of pharmaceutical and biochemical research. This heterocyclic alcohol features a difluoromethyl group attached to a pyrazol ring, making it a structurally intriguing molecule with potential applications in drug discovery and synthetic chemistry. The presence of both fluorine atoms and a hydroxymethyl group introduces unique electronic and steric properties, which are highly valued in medicinal chemistry for modulating bioactivity.

The pyrazol scaffold is well-documented for its role in various biologically active molecules, including nonsteroidal anti-inflammatory drugs (NSAIDs) and antiviral agents. The introduction of a difluoromethyl group at the 1-position of the pyrazole ring is particularly noteworthy, as this moiety is frequently employed to enhance metabolic stability, improve binding affinity, and increase lipophilicity in drug candidates. The hydroxymethyl group at the 3-position further expands the synthetic possibilities, allowing for further derivatization and functionalization.

Recent advancements in computational chemistry and molecular modeling have highlighted the importance of fluorinated heterocycles in drug design. Studies suggest that compounds containing difluoromethyl groups often exhibit improved pharmacokinetic profiles, including increased bioavailability and reduced susceptibility to enzymatic degradation. This has spurred considerable interest in synthesizing and exploring derivatives of 1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol, particularly in the context of developing novel therapeutic agents.

In the context of contemporary research, 1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol has been investigated for its potential role in addressing inflammatory and immunological disorders. The pyrazole ring is known to interact with various biological targets, including enzymes and receptors involved in inflammatory pathways. The additional fluorine atoms are believed to enhance interactions with these targets by increasing electron-withdrawing effects and improving binding entropy. Preliminary studies have shown promising results when this compound is incorporated into molecular frameworks designed to modulate inflammatory cytokine release.

The synthesis of 1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol presents an interesting challenge due to the necessity of introducing both fluorine atoms and a hydroxymethyl group with high selectivity. Modern synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions and organometallic chemistry, have enabled more efficient routes to this compound. These methods often leverage palladium or copper catalysts to facilitate the formation of carbon-fluorine bonds, which are critical for maintaining the structural integrity of the difluoromethyl moiety.

One notable aspect of working with 1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol is its reactivity as an alcohol functional group. The hydroxymethyl side chain can participate in various chemical transformations, including esterification, etherification, and oxidation reactions. This versatility makes it a valuable intermediate in multi-step synthetic strategies aimed at creating more complex pharmacophores. For instance, it can be converted into esters or amides to enhance solubility or improve pharmacokinetic properties.

The incorporation of difluoromethyl groups into biologically active molecules has been extensively studied due to their ability to modulate pharmacokinetic properties such as solubility, permeability, and metabolic stability. In particular, the 2,2-difluoro substitution pattern is known to confer enhanced metabolic resistance against cytochrome P450 enzymes, which are responsible for drug metabolism. This property is particularly advantageous for designing long-acting drugs that require fewer dosing regimens.

Recent publications have explored the use of 1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol as a building block in fragment-based drug design (FBDD). FBDD approaches rely on identifying small molecular fragments that exhibit preliminary biological activity and then optimizing these fragments through iterative synthesis and testing. The unique structural features of this compound make it an attractive candidate for generating novel lead compounds targeting diseases such as cancer and neurodegenerative disorders.

In addition to its pharmaceutical applications, 1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol has potential uses in materials science and agrochemical research. Fluorinated heterocycles are increasingly being explored for their role in developing advanced materials with tailored electronic properties. Similarly, in agrochemistry, fluorinated compounds are valued for their improved stability against environmental degradation and enhanced efficacy as pesticides or herbicides.

The future direction of research involving 1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol will likely focus on expanding its chemical space through further derivatization efforts. By modifying the substituents on the pyrazole ring or introducing additional functional groups, researchers aim to uncover new biological activities and optimize existing ones. Advances in automation and high-throughput screening techniques will accelerate these efforts by enabling rapid evaluation of large libraries of derivatives.

Overall,1-(Difluoromethyl)-1H-pyrazol-3-ylmethanol (CAS No: 1245772-78-4) represents a compelling compound with broad applications across multiple scientific disciplines. Its unique structural features—combining a heterocyclic core with fluorinated substituents—make it a valuable asset in pharmaceutical development programs aimed at addressing unmet medical needs. As synthetic methodologies continue to evolve, the accessibility of this compound will likely increase, further driving innovation in drug discovery and material science.

• 925179-02-8(1-(Difluoromethyl)-1H-pyrazole-3-carboxylic acid)
• 153912-60-8((1,5-Dimethyl-1H-Pyrazol-3-Yl)Methanol)
• 115414-06-7(1-methyl-1H-Pyrazole-3,5-dimethanol)
• 785004-15-1(O-(1-methyl-1H-pyrazol-3-yl)methylhydroxylamine)
• 88529-82-2(O-[(1-methylpyrazol-3-yl)methyl]hydroxylamine)
• 84547-62-6((1-Methyl-1H-pyrazol-3-yl)methanol)
• 84547-61-5((1-Methyl-1H-pyrazol-5-yl)methanol)
• 1245772-28-4(1-(Difluoromethyl)-1H-pyrazol-5-ylmethanol)
• 57012-20-1((1,3-Dimethyl-1H-pyrazol-5-yl)methanol)
• 956628-23-2(1-(Difluoromethyl)-3-methyl-1H-pyrazole)